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Aims Guanylyl cyclase-cyclic guanosinemonophosphate signalling plays an important role in endogenous cardioprotective sig-
nalling.The aimwas to assess thepotential of direct pharmacological activationand stimulationof soluble guanylyl cyclase,
targeting different redox states of the enzyme, to limit myocardial necrosis during early reperfusion.
Methods
and results
Rat isolated hearts were subjected to reversible left coronary artery occlusion (ischaemia-reperfusion) and infarct size was
assessed by the tetrazolium staining technique. Administration during early reperfusion of BAY 41-2272, an NO-
independent, haem-dependent stimulator of soluble guanylyl cyclase targeting the reduced state, or BAY 60-2770, an
NO-independent, haem-independent activator targeting the oxidized state, significantly limited infarct size. Inhibition of
NO synthesis did not abrogate this protection, but exogenous perfusion of NO with BAY 41-2272 produced a synergistic
effect. The haem site oxidiser, ODQ abrogated the protection afforded by BAY 41-2272 but potentiated the protection
affordedbyBAY60-2770.Targeting both the reducedandoxidized formsof sGCtogetherdid not afford additiveprotection.
Conclusions Targeting either reduced or oxidized forms of sGC during early reperfusion affords cardioprotection, providing support
for the concept that direct sGC manipulation at reperfusion has therapeutic potential for the management of acute
myocardial infarction.
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1. Introduction
Guanosine-3′,5′-cyclic monophosphate (cyclic guanosine monopho-
sphate, cGMP) is a secondmessenger generated by soluble and particu-
late guanylyl cyclases (sGC and pGC). Manipulating cGMP signalling
through natriuretic peptide receptors/pGC and NO/sGC can limit the
development of myocardial ischaemia-reperfusion injury.1 Most pertin-
ently, activation of these signalling pathways during the early phase of
reperfusion is associated with marked limitation of infarct size,2–5 an
effect mediated through elevation of intracellular cGMP levels and acti-
vation of protein kinase G (PKG).2
sGC is a heterodimeric proteinwhich incorporates a prosthetic haem
group, required for stimulation by NO, its major biological activator.6,7
It is known that the balance in the redox state of the haem moiety is
shifted from a reduced (Fe2+) state to an NO-insensitive (Fe3+) state
under conditions of oxidative stress.8–10 Since the bioavailability of
NO may be severely compromised in disease states, especially those
associated with oxidative stress,11 a range of directly acting,
NO-independent activators and stimulators have been developed for
the management of vascular diseases. These compounds include
direct NO-independent stimulators of sGC, such as BAY 41-2272,
which bind to the haem moiety in its normal Fe2+ state and stimulate
GTP catalytic activity independently ofNO. Synthetic haem-independent
activators of sGC in the oxidized Fe3+ haem state include BAY
60-2770.8,12,13 It is assumed that the redox balance of sGC under con-
ditions of ischaemia-reperfusion is shifted towards the oxidized form
which is insensitive to NO stimulation.
Since there is evidence that cGMP signalling is a tractable target for
limiting the injurious consequences of reperfusion, we set out to inves-
tigate the infarct-limiting properties of this unique class of compounds
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whosemechanismof action is to stimulate/activate sGC, thereby elevat-
ing cGMP levels independentlyofNO.14–19Theprimaryobjectiveof the
studywas to evaluate the effects of agents that target either the reduced
or oxidized/haem-free states of sGC. It was hypothesized that perfusion
of a sGC stimulator, BAY 41-2272 or activator, BAY 60-2770 during
early reperfusion would limit infarct size and this protection would be
in part as a result of elevated cGMP concentrations in the myocardium.
2. Methods
2.1 Animals
Male Sprague-Dawley rats (300–350 g; from Charles River, UK; B&K Uni-
versal Ltd, UK; or Harlan UK Ltd, UK) were used for these studies. Their
care and use were in accordance with the UK Home Office guidelines on
the Animals (Scientific Procedures) Act 1986 (The Stationary Office
London, UK) and approved by the Cardiff University ethics review board.
Rats were housed in the institutional animal house under 12 h on/12 h off
light cycles and allowed to acclimatize for at least 7 days with the standard
chow containing 4% fat and 18% protein and water available ad libitum.
2.2 Experimental infarction and infarct size
measurement
Rats were anaesthetized by pentobarbital sodium (175 mg/kg) with heparin
(200 units) given concomitantly by i.p. injection. Hearts were excised and
Langendorff perfused with modified Krebs–Henseleit buffer at constant
pressure (74 mmHg) as previously described2 (see Supplementary material
online for full details). Using a fluid filledballoon, left ventricular end-diastolic
pressure (LVEDP) was set between 5 and 10 mmHg and isovolumic devel-
oped pressure continuously recorded (Chart, Powerlab data acquisition
software, ADInstruments, UK). Coronary flow rate (CFR) was measured
by collecting the coronary effluent from the apex of the heart. Before com-
mencing any experimental protocol, hearts were left to equilibrate at 378C
for 10 min using a heated circulator.
Regional ischaemia was induced by placing a reversible suture and snare
occluder around the left main coronary artery close to its origin. Ischaemia
was confirmed by a CFR reduction of .30%. Hearts were subjected to
35 min coronary artery occlusion followed by 120 min reperfusion at
378C. Following reperfusion the coronary artery was ligated and hearts
were perfused with Evans’ Blue dye to stain the non-ischaemic tissue and
thereby delineate the ischaemic risk zone by dye exclusion. Hearts were
then frozen at 2208C, sectioned transversely from the apex into 2 mm
thick sections and incubated in 1% triphenyltetrazolium chloride in phos-
phate buffer (pH 7.4) at 378C to determine the unstained necrotic region
within the ischaemic risk zone. After fixing for 48 h in 4% formaldehyde, sec-
tions were imaged from both sides (ImageJ version 1.45q, NIH, USA) and a
graphics tablet (Trust International B.V., Netherlands) was used to measure
the total tissue area, risk zone, and necrotic zone of each section. These
values were converted into volumes and combined to give total risk zone
volume (R) and infarct size as a percentage of the risk zone (I/R %).
Hearts were included for analysis only if they met strict inclusion criteria
during the experimental protocols. Hearts were excluded if they failed to
develop sinus rhythm during stabilization, if heart rate was ,200 b.p.m.,
baseline CFR .20 mL/min or if left ventricular developed pressure was
,50 mmHg during stabilization. Regional ischaemia was confirmed by a
CFR reduction .30% during coronary artery occlusion. Following release
of the coronary artery snare, successful reperfusion was confirmed by a
return towards baseline of CFR.
2.3 Myocardial cGMP assay
cGMP measurements were made in LV and RV myocardial tissue samples,
harvested from hearts perfused in separate experiments as described
below. Tissue samples were snap frozen, crushed, and immediately added
to 200 mL lysis buffer containing 1 mM 3-isobutyl-1-methylxanthine.
Samples were centrifuged for 60 min at 10 000 g. Supernatants were
re-suspended in400 mL10%trichloroacetic acidand left for30 min followed
by a further centrifugation at 2500 g for 10 min. The supernatant was used
for the cGMPmeasurements using the commercially available cyclic nucleo-
tide radioimmunoassay kit (IBL International GMBH, Germany).
2.4 Treatment protocols
The following pharmacological agents were used in this study. BAY 41-2272
(Sigma-Aldrich, UK) is a sGC stimulator; BAY 60-2770 (gift from Bayer
Pharma AG, Germany) is a sGC activator; NG-nitro-L-arginine methyl
ester (L-NAME, Tocris Bioscience, UK)wasused to inhibitNOsynthase activ-
ity; 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, Tocris Bioscience)
was used to selectively inhibit sGC; 2-(4-carboxyphenyl)-4,4,5,5-tetrameth
ylimidazoline-1-oxyl-3-oxide potassium salt (C-PTIO, Tocris Bioscience)
was used as a scavenger of free NO; 1-hydroxy-2-oxo-3-(N-methyl-6-
aminohexyl)-3-methyl-1-triazene (NOC-9, Sigma-Aldrich) was used as NO
donor. ODQ and BAY 41-2272 were dissolved in DMSO; the final
maximum concentration of DMSO; in modified Krebs–Henseleit buffer
was 0.05% v/v.
Following stabilization, all hearts were randomized to one of the experi-
mental protocols, illustrated in Figure 1 (see Supplementary material
online for details). All drug perfusions were started 5 min before release
of the coronary artery snare until 10 min after reperfusion apart from
L-NAME, C-PTIO, and ODQ which were perfused from 7 min before
release of the snare. In Series 1, the infarct-limiting effects of BAY 41-2272
given at early reperfusion were examined and the relationship to NO and
sGC redox state was interrogated by co-administration of L-NAME,
C-PTIO, and ODQ. In Series 2, the contribution of exogenous NO was
explored using NOC-9. In Series 3, the effects of BAY 60-2770 were exam-
ined to explore the targeting of the oxidized Fe3+or haem-free state of sGC.
Allied to each series, separate groups of hearts were prepared, without
infarct size determination, for biochemical analysis of tissue cGMP concen-
tration as described in Section 2.3.
2.5 Data analysis
Data are presented asmeans+ SEM and analysed usingGraphPad Prism 5.0
(USA). Normal distribution of data was confirmed with the Kolmogorov–
Smirnoff test. Differences in mean values for infarct size, cGMP concentra-
tions, and baseline haemodynamic parameters were compared by
one-way ANOVA and Newman–Keul’s post hoc test. Correlation of
cGMP concentration with infarct size was determined using Spearman’s
rank correlation coefficient. A P-value of ,0.05 was considered significant.
3. Results
Two hundred and eighty-five rats were used for this study. In the infarct
experiments, 19 hearts failed to meet one or more of the inclusion cri-
teria and were excluded from further experimentation. There were no
technical exclusions in the groups prepared for cGMP analysis. Thus, we
report data from 205 infarct experiments and from 61 hearts prepared
for cGMP analysis.
3.1 Cardioprotective effects of sGC
stimulator BAY 41-2272
In Series 1, we investigated the infarct-limiting properties of the sGC
stimulator BAY 41-2272 and explored its dependency on endogenous
NO and its effects on myocardial cGMP concentration.
3.1.1 Infarct size
Baseline haemodynamic data are presented in Table 1. All experimental
groups displayed comparable flow (CFR) and functional (HR, LVDP,
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RPP) parameters at the end of the pre-ischaemic stabilization period.
The ischaemic area at risk of infarction for these groups was 44–55%
of total myocardial volume with no statistically significant differences
between groups. Under control conditions, infarct size was 31.5+
2.8% of the ischaemic risk zone. Treatment at reperfusion with BAY
41-2272 effected a concentration-dependent reduction in infarct size,
maximal at 3 mM the highest concentration employed (17.0+2.1%,
P, 0.05) (Figure 2A). The sGC inhibitor, ODQ 2 mM, which oxidizes
the haem group of the NO binding site in sGC, abrogated the
infarct-limiting effect of BAY 41-2272 (29.6+1.7%) confirming the
need for the haem site to be in its reduced state, although ODQ had no
effect on infarct size per se (Figure 2B). However, in the presence of the
NO synthase inhibitor L-NAME 100 mM, infarct limitation was still
afforded byBAY41-2272 (20.5+2.5%, P, 0.05 vs. control). In the pres-
ence of C-PTIO 30 mM, BAY 41-2272 also produced a significant limita-
tion of infarct size (23.6+0.9%, P, 0.05 vs. control). Neither L-NAME
nor C-PTIO perfused alone had any effect on infarct size (Figure 2C).
3.1.2 Myocardial cGMP concentration
cGMP measurements for Series 1 are presented in Figure 2D. In parallel
groups of hearts subjected to 35 min left coronary artery occlusion and
10 min reperfusion, treatment with BAY 41-2272 (from 5 min before
until 10 min after reperfusion) elicited an approximately two-fold
elevation of cGMP content in both left ventricle subjected to
ischaemia-reperfusion (17.76+ 1.87 vs. 9.44+0.61 fmol/mg tissue,
P, 0.01) and normoxically perfused right ventricle (28.79+3.01 vs.
13.69+ 0.50 fmol/mg tissue, P, 0.01). It is of interest to note that
the cGMP content of naive (non-perfused) hearts was significantly
higher in right ventricle than in left ventricle samples (17.87+ 2.56 vs.
11.28+ 0.54 fmol/mg tissue, P, 0.01).
3.2 Cardioprotective effects of exogenous
NO
In Series 2, we explored the effects of exogenously administered NO,
from the donor compound NOC-9, on limiting infarct size when admi-
nistered during early reperfusion.
3.2.1 Infarct size
The baseline haemodynamic parameters and area at risk for all groups in
this serieswerecomparable betweengroups (Table 1).NOC-9perfused
across the concentration range 1 nM–1 mMat early reperfusion limited
infarct size in a concentration-dependent manner from 34.7+1.6% in
control hearts to 20.5+ 1.3% (P, 0.001) in hearts treated with
NOC-9 at the highest concentration (Figure 3A).
3.2.2 Myocardial cGMP concentration
To further explore the relationship between BAY 41-2272-induced
cardioprotection and NO, cGMP measurements were made in hearts
perfusedwith BAY 41-2272 and concomitantly with either theNO syn-
thase inhibitor L-NAME or the NO scavenger C-PTIO. Tissue samples
from concomitant BAY 41-2272 and L-NAME perfused LV had cGMP
levels 48% lower than those perfused with BAY 41-2272 alone
(11.15+0.91 vs. 17.76+1.87 fmol/mg tissue, P, 0.05). Similarly,
cGMP levels in LV tissue perfused with both C-PTIO and BAY
41-2272 were 54% lower than BAY 41-2272 alone (8.29+0.52 vs.
17.76+ 1.87 fmol/mg tissue, P, 0.001) (Figure 3B).
3.3 Cardioprotective effects of sGC
activator BAY 60-2770
In Series 3, we investigated the infarct-limiting properties of sGC activa-
tion of BAY 60-2770 which targets the oxidized Fe3+ and haem-free
forms of the protein.
3.3.1 Infarct size
Baseline haemodynamic parameters and area at risk for all groups in this
series were comparable between groups (Table 1). The sGC activator
BAY 60-2770 afforded protection across the concentration range
5 nM–1 mM during early reperfusion from 33.0+2.6% in control
hearts to22.0+2.8% (P, 0.01) forhearts treatedwith thehighest con-
centration. However, no concentration effect was observed (Figure 4A).
To confirm the haem independence of BAY 60-2770’s action further
hearts were co-perfused with 2 mM ODQ. Concomitant perfusion of
ODQ with the lowest concentration of BAY 60-2770 (5 nM) limited
Figure 1 Treatment protocol for isolated heart perfusion experiments and cGMP measurement sampling. Hearts used for infarct experiments were
stabilized for 20 min, followed by 35 min of regional ischaemia and 120 min reperfusion. They were treated with one of four protocols. Control experi-
mentswere subjected tonopharmacological intervention (A).Hearts perfusedwith cGMPelevating compounds from30 min ischaemia until 10 min reper-
fusion (B). Hearts perfusedwith inhibitors from 28 min ischaemia until 10 min reperfusion (C). Hearts perfusedwith both cGMPelevating compounds and
inhibitors (D). Arrows indicate time at which tissue was sampled for cGMP analysis. Naive samples were excised, washed in Krebs–Henseleit (E). Stabil-
ization samples were perfused for 20 min (F). Drug-treated and untreated reperfusion samples were subjected to 35 min left descending coronary artery
occlusion and 10 min reperfusion (G).
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infarct size to 17.6+2.0% (P, 0.01 vs. control) (Figure 4B). Perfusion
with ODQ 2 mM alone did not afford protection (32.9+ 2.2%)
(Figure 4B), an effect comparable with that seen in Series 1. Reperfusion
with the NO scavenger C-PTIO produced infarct sizes similar to con-
trols (32.0+2.8%) (Figure 4B). Furthermore, C-PTIO did not abrogate
the protection afforded by BAY 60-2770 (22.2+ 2.2 vs. 33.0+2.6%,
P, 0.01) (Figure 4B). To investigate the protective effect of targeting
both the reduced and oxidized/haem-free forms of sGC, we concomi-
tantly perfused BAY 60-2770 5 nM and BAY 41-2272 1 mM. This com-
bination resulted in only a modest 21% reduction in infarct size
(24.8+2.7%, P, 0.05 vs. control) (Figure 4B).
3.3.2 Myocardial cGMP concentration
Tissue levels of cGMP were measured in hearts that had been perfused
with or without BAY 60-2770 and subjected to 35 min regional ischae-
mia. Measurements were also made in hearts perfused with BAY
60-2770 concomitantly with ODQ or a sub-maximal concentration of
BAY 41-2272. In LV samples, cGMP levels were not elevated in tissue
that had been perfused with BAY 60-2770 compared with samples
that had not (12.60+1.65 vs. 9.20+ 0.70 fmol/mg tissue). Tissue
samples perfused with concomitant BAY 60-2770 and ODQ had
cGMP levels 60% higher than those perfused with BAY 60-2770 alone
(20.16+2.25 vs. 12.60+1.65 fmol/mg tissue, P, 0.01). An increase
of 36% was also seen in LV samples perfused with both the sGC stimu-
lator and activator compared with the activator alone (17.11+1.90 vs.
12.60+ 1.65 fmol/mg tissue, P, 0.05), an increase of 86% compared
with untreated hearts (17.11+1.90 vs. 9.20+0.70 fmol/mg tissue,
P, 0.05) (Figure 4C).
4. Discussion
The principal findings of these studies can be summarized as follows.
(1) Targeting the reduced form of sGC during early reperfusion with
the stimulator BAY 41-2272 afforded concentration-dependent
infarct limitation and this protection was independent of endogen-
ous NO, demonstrated with concomitant perfusion of BAY
41-2272 and the NOS inhibitor L-NAME or NO scavenger
C-PTIO. Tissue cGMP concentrations during early reperfusion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline cardiodynamic data for infarct experiments in series 1, 2, and 3
Series Treatment group
(number)
n CFR
(mL/min)
HR
(BPM)
LVDP
(mmHg)
RPP (mmHg/
min3 103)
Vol. LV and
RV (cm3)
Risk zone
vol. (cm3)
Risk zone (%
vol. LV and
RV)
1 Control (1) 17 14.6+1.0 272+8 69.3+4.3 18.9+1.4 0.95+0.03 0.39+0.03 44.7+2.4
BAY 41 100 nM (2) 7 17.3+1.0 296+12 62.7+4.6 18.7+1.7 0.87+0.03 0.42+0.04 47.9+3.6
BAY 41 300 nM (3) 6 15.3+0.7 295+10 59.7+3.9 17.6+1.1 0.87+0.05 0.40+0.06 45.7+4.7
BAY 41 1 mM (4) 6 18.1+1.3 293+11 69.2+4.5 20.3+1.5 0.91+0.04 0.46+0.08 49.2+6.3
BAY 41 3 mM (5) 7 17.1+1.2 296+18 69.7+4.7 21.0+2.6 0.95+0.03 0.48+0.04 50.1+3.7
ODQ 2 mM + BAY 41
3 mM (6)
7 15.7+0.8 311+10 80.0+8.7 24.4+2.0 1.01+ 0.04 0.46+0.03 46.4+2.1
ODQ 2 mM (7) 6 14.7+1.2 315+21 70.7+10.5 21.7+2.3 0.98+0.02 0.44+0.04 45.4+3.3
L-NAME 100 mM + BAY 41
3 mM (8)
8 15.3+0.6 290+9 68.4+6.3 19.5+1.3 0.96+0.05 0.47+0.03 49.9+2.0
L-NAME 100 mM (9) 6 13.8+0.7 309+17 61.2+1.8 18.3+1.0 0.89+0.27 0.44+0.03 50.6+3.8
C-PTIO 30 mM + BAY 41
3 mM (10)
6 16.8+0.7 298+6 63.1+3.6 18.8+1.0 1.07+0.03 0.52+0.03 49.7+4.0
C-PTIO 30 mM (11) 6 15.7+0.7 313+6 64.5+4.8 20.2+1.5 1.03+0.05 0.54+0.04 53.4+4.3
2 Control (12) 12 14.6+0.6 313+10 66.0+6.6 20.4+1.7 0.81+0.04 0.35+0.03 42.6+2.9
NOC-9 1 nM (13) 6 14.9+1.1 327+11 69.9+4.8 22.4+1.4 0.81+0.06 0.39+0.03 48.2+2.1
NOC-9 10 nM (14) 6 15.2+0.8 322+8 70.1+6.1 21.9+1.2 0.83+0.04 0.41+0.02 49.4+ 3.6
NOC-9 100 nM (15) 6 14.4+0.2 329+14 63.9+8.7 20.5+1.9 0.82+0.03 0.45+0.02 54.6+3.7
NOC-9 1 mM (16) 9 15.9+0.8 341+4 69.0+4.9 22.9+1.8 0.79+0.02 0.40+0.02 50.6+3.3
3 Control (17) 18 16.8+0.6 315+6 65.9+3.1 20.7+0.9 0.82+0.02 0.39+0.02 47.9+2.2
BAY 60 5 nM (18) 6 17.3+1.0 319+15 69.0+5.0 22.1+2.0 0.79+0.03 0.36+0.02 46.0+2.1
BAY 60 50 nM (19) 8 16.1+1.0 331+5 68.1+4.0 22.5+1.4 0.80+0.02 0.40+0.03 52.3+3.3
BAY 60 500 nM (20) 8 14.6+0.6 322+7 68.7+3.7 22.1+1.3 0.80+0.05 0.34+0.02 42.7+1.8
BAY 60 1 mM (21) 7 16.5+1.1 336+4 69.6+ 4.8 23.4+1.4 0.85+0.02 0.46+0.04 54.2+4.1
ODQ 2 mM (22) 6 16.9+0.9 316+7 61.9+1.7 19.6+0.7 0.85+0.04 0.37+0.03 55.8+3.5
BAY 60 5 nM + ODQ
2 mM (23)
7 15.5+1.0 310+7 69.5+4.8 21.5+1.7 0.86+0.05 0.35+0.05 43.1+2.8
BAY 60 5 nM + C-PTIO
30 mM (24)
6 14.1+0.7 333+4 73.9+6.6 24.7+2.3 0.84+0.01 0.38+0.03 45.6+3.4
C-PTIO 30 mM (25) 6 14.7+0.8 320+6 67.4+7.5 21.5+2.4 0.85+0.05 0.35+0.01 41.7+2.9
BAY 41 1 mM (26) 6 14.1+0.6 313+9 69.5+4.4 21.6+0.9 0.84+0.02 0.32+0.02 38.6+ 1.6
BAY 60 5 nM + BAY 41
1 mM (27)
6 15.2+1.6 323+9 68.6+5.3 22.1+1.8 0.84+0.02 0.38+0.02 45.5+2.9
No statistical difference between groups within each series (P. 0.05).
CFR, coronary flow rate; HR, heart rate; LVDP, left ventricular developed pressure; RPP, rate pressure product (HR × LVDP); LV, left ventricle; RV, right ventricle.
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wereelevatedby the sGCstimulator.Theobservedelevationswere
partly independent of NO.
(2) Perfusion of the NO donor NOC-9 during early reperfusion
demonstrated concentration-dependent infarct limitation. Target-
ing the oxidized state of sGC with BAY 60-2770 also afforded
infarct limitation. However, the protection observed was not
increased beyond that seen with the sGC stimulator. Concomitant
perfusion of both the sGC stimulator and activator did not afford
greater protection than either treatment alone.
(3) Concomitant perfusion of BAY 60-2770 and ODQ elevated
total cGMP concentration beyond BAY 60-2770 only perfused
myocardium.
(4) Infarct size and left ventricular cGMP content measured at 10 min
reperfusion analysed for correlation did not meet significance, sug-
gesting that elevation of total LV cGMP levels are not imperative to
afford protection (Figure 5).
NO/sGC/cGMPsignalling during early reperfusionhas been shownto
be a tractable target to limit infarct size.However, the literature is incon-
sistent in reporting the protective effects of NO donors.2,20,21 Elevating
cGMP levels during the first minutes of reperfusion is recognized as a
contributory mechanism in the reperfusion injury salvage kinase signal-
ling paradigm.1,22,23 Previous work by us and others has documented
Figure 2 Infarct size data for BAY 41-2272 concentration response (A), concomitant perfusion of the haem site oxidiser ODQ (B) and NO inhibitors
(C) expressed as infarct to-risk ratio %. Data are means+ SEM. *P, 0.05, **P, 0.01 vs. control (one-way ANOVA). Total cGMP concentrations in LV
(solid) and RV (open) myocardial tissue samples (D). **P, 0.01 vs. respective reperfusion (10’R) control. (one-way ANOVA) n ¼ 5–17.
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that administration of natriuretic peptides during early reperfusion
limits infarct size in both the rabbit and rat.2–4,22 Furthermore,
this protection was mediated through elevated cGMP concentration
and PKG-dependent mechanisms. The sGC activator BAY 58-2667
(Cinaciguat) has been shown to limit infarct size at reperfusion, again
by elevating cGMP concentrations.20,23,24 This demonstrates that the
oxidized and/or haem-free formsof sGCare present in themyocardium
during reperfusion and can be targeted to elevate cGMP.
To explore the infarct-limiting properties of pharmacological agents
that elevate cGMP, we used both a sGC stimulator and a sGC activator.
Our initial results demonstrated that perfusion of the sGC stimulator
during early reperfusion limited infarct size in a concentration-
dependent manner. It was then demonstrated that the protection
afforded was at least in part as a result of elevated cGMP levels during
early reperfusion. To characterize the mechanistic action of BAY
41-2272 further, ODQ was concomitantly perfused which abrogated
the protection afforded by the stimulator alone. This is in agreement
with the cell-based studies reported by Stasch et al.14 who reported
that sGC stimulation by BAY 41-2272 was haem-dependent requir-
ing the haem moiety to be in the Fe2+ state for enzymatic activity.19,25
The relaxant effects of BAY 41-2272 to rat tracheal rings was dampened
in preparations pre-incubated with L-NAME or ODQ.26 To investigate
theNOcomponentofBAY41-2272action, the sGCstimulatorwasper-
fused concomitantly with either L-NAME or C-PTIO. In both instances
the infarct-limiting effects of BAY 41-2272 could not be completely
abrogated, confirming that in terms of infarct limitation, the stimulator
affords protection independently of NO. The results do however
suggest that there is an NO component to the protection observed.
Stasch et al.14 reported that PTIO at high concentrations could not
block sGC stimulation.
Since reports that exogenous NO can afford infarct limitation when
perfused during early reperfusion have been inconsistent, we carried
out experiments using NOC-9, a rapid release NO donor.27 We were
able to demonstrate a concentration-dependent action of the NO
donor, limiting infarct size by half at the highest concentration. The
current data are supported by previous experiments that demonstrate
the need to recruit eNOS in reperfusion salvage.3,20
Using the sGC activator BAY 60-2770, we investigated the
infarct-limiting effects of targetingwhatmay be regarded as a pathologic-
al stateof the enzyme.Cohen et al.20 andKrieg et al.23 demonstrated that
perfusion of the structurally similar BAY 58-2667 could limit infarct size
in both the rat and the rabbit in a global model of ischaemia-reperfusion.
Our results support this work and confirm that there indeed must be a
component of the so-called pathological sGC present during early
reperfusion. Infarct size limitation reported by Cohen et al.20 and
Krieg et al.23 was much more marked than in the present study,
matched by a larger percentage increase in cGMP. In contrast to our
own studies; however, the basal concentrations of cGMP measured
were much lower. Additionally, we perfused hearts with the sGC
activator concomitantly with ODQ. These results confirm the haem-
independent action of BAY 60-2770 and suggest that the concomitant
therapy limited infarct size beyond the activator alone. More convincing
were the cGMPmeasurementsmade in comparable experimentswhich
showed that oxidizing the haem groupwithODQrendered the enzyme
more sensitive to the activator, demonstrated by the larger elevation of
total LV cGMP following concomitant perfusion.
Figure 3 Infarct size data for NOC-9 concentration response (A), expressed as infarct to-risk ratio %. Data are means+ SEM. *P, 0.05, **P, 0.01,
***P, 0.001 vs. control (one-wayANOVA). Total cGMPconcentrations in LV (solid) andRV (open)myocardial tissue samples (B). *P, 0.05, **P, 0.01,
and ***P, 0.001 vs. 10’R BAY 41 (one-way ANOVA) n ¼ 5–12.
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To explore the benefits of targeting both redox states of sGC during
early reperfusion, we co-perfused submaximal concentrations of both
the sGC stimulator and the activator to ascertain whether targeting
both redox statescould affordgreater infarct limitation thaneither treat-
ment alone. Our results demonstrate that in terms of infarct limitation,
concomitant perfusionof both compoundsdoes not potentiate thepro-
tection observed by the other compound. Furthermore, infarct sizewas
greater when both compounds were perfused together comparedwith
the sGC activator alone. A possible explanation for these results could
lie in physical or chemical interactions of the compounds at the target
site on sGC. Although the sites of action of both compounds differ,
they may impede each other’s action when in close proximity.
However, the subsequent results refute this speculation with elevation
of LV cGMP measured in comparable experiments. Concentrations
were significantly elevated above those of BAY 60-2270 only treated
hearts, comparable with those of hearts perfused with the sGC sti-
mulator BAY41-2272. These data suggest that both compounds were
able to elicit a response in the presence of the other. Previous work
from our laboratory demonstrated that the cGMP analogue 8-Br-
cGMP had a deleterious effect on infarct size at high concentrations,
suggesting that excess cGMP may inhibit the protective effect of lower
concentrations.22
Figure 4 Infarct size data for BAY 60-2770 concentration response (A), concomitant perfusion of the haem site oxidiserODQ,NO scavenger C-PTIO,
and BAY 41-2272 (B) expressed as infarct to-risk ratio %. Data aremeans+ SEM. *P, 0.05, **P, 0.01 vs. control (one-way ANOVA). Total cGMP con-
centrations in LV (solid) and RV (open) myocardial tissue samples (C). **P, 0.01 and ***P, 0.001 vs. 10’R BAY 60. #P, 0.05 and ##P, 0.01 vs. 10’R
(one-way ANOVA) n ¼ 5–18.
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For the first time, we plotted total LV cGMP levels against infarct size
across a range of corresponding treatment groups (Figure 5). Although
there is a trend towards infarct limitation with increased total LV
cGMP concentration, correlation analysis did not reach significance
(P ¼ 0.07). This data set suggests that affording protection goes
beyond gross elevation of LV cGMP. Most surprising are the results
for LV cGMP measurements in hearts perfused concomitantly with
BAY 41-2272 and either L-NAME or C-PTIO. Although a modest pro-
tective state is achieved, cGMP levels are not elevated above baseline.
This suggests that the gross elevation seen in BAY 41-2272 only
treated hearts requires the presence of NO. Similarly, hearts protected
with BAY 60-2770 did not showa significant elevation in total LV cGMP,
whereas those perfused concomitantly with ODQ did.
There is a growing bodyof evidence to suggest that cGMP is compart-
mentalized within discrete subcellular domains, regulated by specific
PDEs and guanylyl cyclases.28,29 We can only speculate that affording
infarct limitation by targeting cGMP requires specific targeting of dis-
crete pools and not gross LV elevation. What we may be missing in
the current data set is that total LV cGMPmay not be elevated, yet spe-
cific protective pools maybe, without net elevation. Conversely, the
ability to resolve local protective cGMP elevation may be masked in
groups where total LV cGMP is elevated. This has led us to make refer-
ence to the notion that there may be specific ‘cytoprotective cGMP
pools’. This thesis is yet to be explored in the ischaemia-reperfusion
setting as the ability to visualize/quantify changes in discrete subcellular
cGMP is in its infancy. In addition, how the redox balance of sGC shifts
during early reperfusion and how it affects distribution and production
of cGMPwould also be worthy of exploration and support this thesis.30
In conclusion, these studies demonstrate that targeting sGC during
early reperfusion following simulated AMI is a tractable target to limit
infarct size. Using cGMP elevating compounds provides a more specific
target in comparison with NO donors which are associated with vascu-
lar tolerance and non-desirable effects.11,31 The current study corrobo-
rates in vitromechanistic studies. These data do not directly support the
hypothesis that targeting the so-called pathological state of sGC is a
moreattractive target duringearly reperfusion; nevertheless, quantifying
the spatial differences of the sGC redox state, the extent of shift during
the criticalmoments and the specific localized changes in cGMPconcen-
tration remains desirable.
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